J Gynecol Oncol.  2015 Apr;26(2):87-89. 10.3802/jgo.2015.26.2.87.

FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication

• Prat J
• FIGO Committee on Gynecologic Oncology

• KMID: 2160790
• DOI: http://doi.org/10.3802/jgo.2015.26.2.87

Abstract

No abstract available.

MeSH Terms

Fallopian Tube Neoplasms/classification/*pathology
Female
Gynecology/organization & administration/standards
Humans
International Agencies
Neoplasm Staging/methods/*standards
Obstetrics/organization & administration/standards
Ovarian Neoplasms/classification/*pathology
Peritoneal Neoplasms/classification/*pathology
*Practice Guidelines as Topic

Reference

1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer;2014.

2. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012; 460:237–249.

3. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009; 40:1213–1223.

4. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195:451–456.

5. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007; 25:3985–3990.

6. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007; 31:161–169.

7. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95:Suppl 1. S161–S192.

8. Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/ II patients and superior survival to other Stage III patients. Cancer. 1998; 83:1555–1560.

9. Kanazawa K, Suzuki T, Tokashiki M. The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Gynecol Oncol. 1999; 73:237–241.

10. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005; 97:560–566.

11. Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol. 2006; 103:797–801.

12. Ferrandina G, Scambia G, Legge F, Petrillo M, Salutari V. Ovarian cancer patients with "node-positive-only" Stage IIIC disease have a more favorable outcome than Stage IIIA/B. Gynecol Oncol. 2007; 107:154–156.

13. Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, et al. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol. 2008; 19:223–228.

14. Bakkar R, Gershenson D, Fox P, Vu K, Zenali M, Silva E. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses. Int J Gynecol Pathol. 2014; 33:302–308.